Pliant Therapeutics Inc (PLRX)
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker PLRX. The company is focused on discovering and developing integrin-based therapies, with an emphasis on treatments for solid tumors. Its lead candidate, PLN-101095, is an oral small-molecule dual inhibitor of avß8 and avß1 integrins that is being evaluated in Phase 1a/1b testing for solid tumors. Pliant Therapeutics also maintains a drug discovery platform built around a proprietary library of more than 15,000 integrin-binding molecules, supporting its work in integrin-based target-mediated drug delivery. Incorporated in 2015, the company is headquartered in South San Francisco, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PLRX
|
$1.53
|
33.8% Upside
|
Undervalued
|
$2
|
75.4% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
0.5x
|
70.591 M
|
-60.625 M
|
28.9%
|
88.9%
|
-6.8
|
76.8%
|
